Chs Pharma Inc
CHS Pharma Inc. on Feb. 2013 acquired its Intellectual Property Portfolio from Florida Atlantic University and Hospital for Special Surgery. The IP portfolio is considered a platform technology and currently consists of 4 issued patents, 2 allowed, and 8 applications pending. The mentioned portfolio covers drug candidates for treatments of Actinic Keratosis (Basal and Squamous cell Carcinomas in EU patent), Dry Macular Degeneration, Myocardial Infarction, and Ischemic Stroke. CHS's corporate development strategy is to develop the drug candidates up to Phase II clinical studies and at that point in time either form a strategic partnership or license the technology to other pharmaceutical companies.
7-day free trial · no credit card
Verified contacts
4
available on Kipplo
LinkedIn employees
4
1 to 10 range
Open roles
—
no listings
Distinct roles
4
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 4 verified contacts at Chs Pharma Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
4 contacts with verified email or phone · masked until revealed.
- DC
David C Rubin
Director of Investor Relations · General Business & Management
EmailPhone - SC
Stephen Chakoff
Director · General Business & Management
EmailPhone - TS
Tatiana Sharon
Assistant to Director of Investments of Chs Pharma · Other
EmailPhone
Showing 3 of 4 verified contacts
Top roles at Chs Pharma Inc
4 distinct titles indexed · top 4 shown.
- 1administrative assistant
- 1assistant to director of investments of chs pharma
- 1director
- 1director of investor relations
Sign up to unlock all 4 contacts at Chs Pharma Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 4 verified contacts at Chs Pharma Inc
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.